Cybrexa Presents New Data for CBX-12 and CBX-13 at the AACR Virtual Annual Meeting II

Cybrexa Poster – CBX13 Cybrexa Poster – CBX12

This week we are presenting new preclinical data for our lead program, CBX-12 (alphalex-exatecan) and CBX-13 (alphalex-DM4) at the AACR Virtual Annual Meeting II.

https://vcusa.sparx-ip.net/aacr2020ep/?view=1&searchfor=cybrexa&c=a&item=2020AB_6249

https://vcusa.sparx-ip.net/aacr2020ep/?view=1&searchfor=cybrexa&c=a&item=2020AB_6242

Previous PostPrevious Cybrexa Therapeutics is Presenting, Speaking on a Panel at BIO Digital June 8-12, 2020

Next PostNext Cybrexa at the 2020 BTIG Virtual Biotechnology Conference (August 10-11)

Search for:

about

Mission
technology
team

Technology

technology story
targeted impact
how it works
applications

pipeline

Development
Pipeline Objectives
Featured Publications

news

press releases
media coverage
events

partners

careers

open positions

Contact us

legal